# Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)

Study · id `cardio:ct-nct02044653` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02044653](<https://clinicaltrials.gov/study/NCT02044653>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02044653

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.

## Technical summary

Registry record NCT02044653. Randomized; single masking; primary purpose treatment. Start 2014-04-15 (actual); primary completion 2017-04-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 257 participants (enrolled count; ClinicalTrials.gov record NCT02044653, source copy `cardio:ctgov-nct02044653-2017-10-16`, retrieved 2026-10-26)
- Started: 2014-04-15 (actual) (ClinicalTrials.gov record NCT02044653, source copy `cardio:ctgov-nct02044653-2017-10-16`, retrieved 2026-10-26)
- Primary completion: 2017-04-20 (actual) (ClinicalTrials.gov record NCT02044653, source copy `cardio:ctgov-nct02044653-2017-10-16`, retrieved 2026-10-26)
- Completion: 2017-04-20 (actual) (ClinicalTrials.gov record NCT02044653, source copy `cardio:ctgov-nct02044653-2017-10-16`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02044653, source copy `cardio:ctgov-nct02044653-2017-10-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02044653-2017-10-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
- Condition: Anemia
- Condition: Chronic Kidney Disease
- Intervention (Drug): GX-E2
- Intervention (Drug): GX-E2
- Intervention (Drug): GX-E2
- Intervention (Drug): NESP
- Intervention (Drug): MIRCERA
- Lead sponsor: Genexine, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 8a51b212bcb8f03595a9d565cd5c3d737de4691609025ffd52402ce7707b0580
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
